ECSP099499A - Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas - Google Patents

Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas

Info

Publication number
ECSP099499A
ECSP099499A EC2009009499A ECSP099499A ECSP099499A EC SP099499 A ECSP099499 A EC SP099499A EC 2009009499 A EC2009009499 A EC 2009009499A EC SP099499 A ECSP099499 A EC SP099499A EC SP099499 A ECSP099499 A EC SP099499A
Authority
EC
Ecuador
Prior art keywords
compound
treatment
benzotriazinone
replaced
increase
Prior art date
Application number
EC2009009499A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Cortex Pharma Inc filed Critical Servier Lab
Publication of ECSP099499A publication Critical patent/ECSP099499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en las sinapsis en las redes cerebrales responsables de comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con la alteración de la memoria, tal como se observa en una variedad de demencias, y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de dichas condiciones, y a métodos para utilizar este compuesto para dicho tratamiento.
EC2009009499A 2007-01-03 2009-07-07 Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas ECSP099499A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
ECSP099499A true ECSP099499A (es) 2009-10-30

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009499A ECSP099499A (es) 2007-01-03 2009-07-07 Compuesto [1, 2, 3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatérgicas

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674321A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
JP5694765B2 (ja) 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ, インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (zh) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) * 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3436021B1 (en) 2016-03-29 2026-07-29 RespireRx Pharmaceuticals, Inc. Compositions comprising low impact ampakines for treating attention deficit disorders
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
DE69331761T2 (de) 1992-07-24 2002-09-12 The Regents Of The University Of California, Oakland Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
WO2003045315A2 (en) * 2001-11-26 2003-06-05 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2674321A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
JP5694765B2 (ja) * 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ, インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
NZ584098A (en) 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
CA2674460A1 (en) 2008-07-17
ZA200904826B (en) 2010-09-29
US20100137295A1 (en) 2010-06-03
TN2009000277A1 (en) 2010-10-18
MX2009007242A (es) 2009-09-02
CU23804B7 (es) 2012-03-15
EA200900925A1 (ru) 2009-12-30
MA31160B1 (fr) 2010-02-01
ATE527269T1 (de) 2011-10-15
RS52108B (sr) 2012-08-31
IL199651A0 (en) 2010-04-15
SG163545A1 (en) 2010-08-30
CU20090117A7 (es) 2011-10-05
ES2374995T3 (es) 2012-02-23
CR10906A (es) 2009-10-23
CA2674460C (en) 2014-07-15
ME00819B (me) 2012-03-20
AP2502A (en) 2012-10-23
HRP20110970T1 (hr) 2012-01-31
PL2144506T3 (pl) 2012-04-30
JP2010514838A (ja) 2010-05-06
JP5139446B2 (ja) 2013-02-06
WO2008085506A1 (en) 2008-07-17
EA017437B1 (ru) 2012-12-28
EP2144506A4 (en) 2010-05-05
AU2007342365B2 (en) 2012-11-15
AP2009004931A0 (en) 2009-08-31
AU2007342365A1 (en) 2008-07-17
MY154877A (en) 2015-08-14
IL199651A (en) 2015-08-31
NZ578293A (en) 2012-01-12
HN2009001268A (es) 2011-12-27
HK1140105A1 (en) 2010-10-08
AR064740A1 (es) 2009-04-22
CN101616592B (zh) 2013-06-05
BRPI0720749A2 (pt) 2014-01-14
NI200900131A (es) 2010-03-11
CY1112493T1 (el) 2015-12-09
US8173644B2 (en) 2012-05-08
SV2009003322A (es) 2010-02-05
EP2144506B1 (en) 2011-10-05
DK2144506T3 (da) 2012-03-05
SI2144506T1 (sl) 2012-01-31
CN101616592A (zh) 2009-12-30
GT200900189A (es) 2011-08-02
PT2144506E (pt) 2011-12-21
EP2144506A1 (en) 2010-01-20
GEP20125438B (en) 2012-03-26

Similar Documents

Publication Publication Date Title
CU23804B7 (es) Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
EA201491534A1 (ru) Ингибиторы бета-секретазы
JO3070B1 (ar) عوامل لمعالجة إضطرابات تتضمن تعديل مستقبلات الريانودين
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
PL2318035T3 (pl) Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
MX2018011453A (es) Moduladores alostericos de receptores de acetilcolina nicotinicos.
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
CL2012003212A1 (es) Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson.
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
WO2014035860A8 (en) Inhibitors of beta-secretase
BR112013018296A2 (pt) tratamento de disfunções cognitivas em esquizofrenia
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
EP2552473A4 (en) METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
DE602008004563D1 (de) Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
GT200900150A (es) Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.